Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FUJME
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $3,424.46 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector units. The award was issued on November 12, 2025, with an ultimate completion date of December 4, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 billion acquisition vehicle designed to provide comprehensive pharmaceutical and medical consumable support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the DoD pharmaceutical supply chain, with a product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's IDC contract, designated SPE2DR and awarded on November 13, 2025, features a ceiling value of $499,999,999 with completion through December 31, 2036, and includes a 30-month base period with three 30-month option periods. As one of multiple regional prime vendor contractors under the broader PPV-G GEN V strategy, DMS Pharmaceutical Group is positioned to serve as a key pharmaceutical supplier for DoD military healthcare operations globally, with Xolair (omalizumab) representing one of the specialized biologic agents within its extensive therapeutic portfolio supplied to federal agencies.
Quick answers
Who was awarded contract SPE2DB26FUJME?
SPE2DB26FUJME was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DB26FUJME worth?
The government has obligated $3,424 on SPE2DB26FUJME.
Is contract SPE2DB26FUJME an order under another contract?
Yes. SPE2DB26FUJME is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB26FUJME competed?
The extent of competition for SPE2DB26FUJME was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award